The idiopathic inflammatory myopathy (IIM) landscape is evolving rapidly, transforming how clinicians recognize disease, assess risk, and select treatment, but translating these advances into everyday practice remains a challenge. As biomarkers and myositis-specific autoantibodies enable increasingly precise subtype classification, clinicians …
Effective pain management is more complex than ever. As opioid prescribing guidance continues to evolve, clinicians must stay current with the latest evidence to deliver safe and patient-centered care. The FDA Opioid Analgesic REMS Education Blueprint and the 2022 CDC …
More than 40% of U.S. adults now live with obesity, and incretin-based therapies have transformed what treatment can achieve. Yet the same clinical experience that produced those gains has exposed their limits: response varies widely from patient to patient, persistence …
Chronic inflammatory demyelinating polyneuropathy (CIDP) presents ongoing diagnostic and therapeutic challenges due to its clinical heterogeneity, evolving pathophysiology, and inconsistent responses to standard treatment. Many health care professionals, particularly those in neurology-focused settings, require current and ongoing education on recognizing …
Chronic lymphocytic leukemia (CLL) has undergone a remarkable therapeutic transformation with the availability of highly effective targeted therapies. However, molecular testing and the integration of prognostic and predictive biomarkers into treatment decisions remain inconsistent, particularly outside tertiary care centers. Because …
Idiopathic hypersomnia (IH) is a life-disrupting condition characterized by excessive daytime sleepiness (EDS) that makes waking up a daily struggle, limits productivity, and erodes overall quality of life. For many patients with IH, the journey to diagnosis is long and …
For people living with ulcerative colitis (UC), cycles of remission and relapse can disrupt daily life and complicate long-term management. Sphingosine-1-phosphate receptor modulators (S1Prms) are a new class of targeted oral therapies with the potential to reduce colonic inflammation and …
Complicated urinary tract infections (cUTIs) represent one of the most challenging and rapidly evolving areas of infectious disease management. Often more severe and harder to treat than standard UTIs, cUTIs are associated with underlying structural or functional abnormalities of the …
Fibrosis remains one of the greatest unmet needs in inflammatory bowel disease (IBD), contributing to irreversible structural bowel damage, complications, and long-term morbidity despite advances in anti-inflammatory therapies. Many gastroenterologists and multidisciplinary gastrointestinal (GI) care teams lack confidence in recognizing …